Matinas Biopharma Holdings, Inc

MTNB

$0.586

Name : Matinas Biopharma Holdings, Inc

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,754,028.00

EPSttm : -3.42

Matinas Biopharma Holdings, Inc

$0.586

0.17%

$0.001

Float Short %

0.21

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.57

Target Price

Analyst Recom

Performance Q

-68.66

Relative Volume

1.71

Beta

1.27

Ticker: MTNB

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-02	MTNB	0.8088	N/A	N/A	0
2025-12-03	MTNB	0.7503	N/A	N/A	0
2025-12-04	MTNB	0.795	N/A	N/A	0
2025-12-05	MTNB	0.7786	N/A	N/A	0
2025-12-08	MTNB	0.8945	N/A	N/A	0
2025-12-09	MTNB	0.8477	N/A	N/A	0
2025-12-10	MTNB	0.82	N/A	N/A	0
2025-12-11	MTNB	0.805	N/A	N/A	0
2025-12-12	MTNB	0.8099	N/A	N/A	0
2025-12-15	MTNB	0.735	N/A	N/A	0
2025-12-16	MTNB	0.751	N/A	N/A	0
2025-12-17	MTNB	0.73	N/A	N/A	0
2025-12-18	MTNB	0.7452	N/A	N/A	0
2025-12-19	MTNB	0.7253	N/A	N/A	0
2025-12-22	MTNB	0.739	N/A	N/A	0
2025-12-23	MTNB	0.6721	N/A	N/A	0
2025-12-26	MTNB	0.6201	N/A	N/A	0
2025-12-29	MTNB	0.61	N/A	N/A	0
2025-12-30	MTNB	0.5701	N/A	N/A	0
2025-12-31	MTNB	0.5702	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-02	MTNB	0.81	-	-	-
2025-12-03	MTNB	0.75	-	-	-
2025-12-04	MTNB	0.77	-	-	-
2025-12-05	MTNB	0.79	-	-	-
2025-12-08	MTNB	0.89	-	-	-
2025-12-09	MTNB	0.84	-	-	-
2025-12-10	MTNB	0.83	-	-	-
2025-12-11	MTNB	0.81	-	-	-
2025-12-12	MTNB	0.80	-	-	-
2025-12-15	MTNB	0.73	-	-	-
2025-12-16	MTNB	0.73	-	-	-
2025-12-17	MTNB	0.76	-	-	-
2025-12-18	MTNB	0.76	-	-	-
2025-12-19	MTNB	0.76	-	-	-
2025-12-22	MTNB	0.73	-	-	-
2025-12-23	MTNB	0.67	-	-	-
2025-12-26	MTNB	0.61	-	-	-
2025-12-29	MTNB	0.58	-	-	-
2025-12-30	MTNB	0.57	-	-	-
2025-12-31	MTNB	0.57	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-02	MTNB	0.00	2.51	0.67
2025-12-03	MTNB	0.00	2.51	0.67
2025-12-04	MTNB	0.00	2.51	0.67
2025-12-05	MTNB	0.00	2.51	0.67
2025-12-08	MTNB	0.00	0	0.67
2025-12-09	MTNB	0.00	0	0.67
2025-12-10	MTNB	0.00	0	0.41
2025-12-11	MTNB	0.00	0	0.41
2025-12-12	MTNB	0.00	0	0.41
2025-12-15	MTNB	0.00	0	0.39
2025-12-16	MTNB	0.00	0	0.39
2025-12-17	MTNB	0.00	0	0.39
2025-12-18	MTNB	0.00	0	0.39
2025-12-19	MTNB	0.00	0	0.39
2025-12-22	MTNB	0.00	2.52	0.39
2025-12-23	MTNB	0.00	2.52	0.39
2025-12-26	MTNB	0.00	2.52	0.21
2025-12-29	MTNB	0.00	2.52	0.21
2025-12-30	MTNB	0.00	2.52	0.21
2025-12-31	MTNB	0.00	2.52	0.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.78

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

2.52

Beta

1.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.4

Target Price

P/E

Forward P/E

PEG

P/S

P/B

0.54

P/Free Cash Flow

EPS

-3.41

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.71

Return on Equity vs Sector %

-297.9

Return on Equity vs Industry %

-282.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Matinas Biopharma Holdings, Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 3

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

stock quote shares MTNB – Matinas Biopharma Holdings Inc Stock Price stock today

news today MTNB – Matinas Biopharma Holdings Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MTNB – Matinas Biopharma Holdings Inc yahoo finance google finance

stock history MTNB – Matinas Biopharma Holdings Inc invest stock market

stock prices MTNB premarket after hours

ticker MTNB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MTNB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y